1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

600276.SS
Jiangsu Hengrui Medicine Co., Ltd.CN flagShanghai Stock Exchange
55.36
CNY
-1.41
- -
353.14BMarket Cap
Jiangsu Hengrui Medicine Co., Ltd.
600276.SS
(Shanghai Stock Exchange)

Recent

price

55.36

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.6
0.72
0.86
0.98
1.18
1.47
1.75
2.17
2.74
3.64
4.34
4.06
3.32
3.61
4.42
4.88
4.83
Revenue per Share
0.12
0.14
0.17
0.2
0.24
0.34
0.41
0.5
0.64
0.83
0.99
0.71
0.61
0.68
1
1.19
1.18
Basic EPS, GAAP
0.02
- -
0.08
0.14
0.2
0.3
0.23
0.34
0.35
0.51
0.45
0.4
-0.11
0.97
0.86
1.28
-0.36
Free Cash Flow per Basic Share
0.01
0.01
0.02
0.02
0.02
0.02
0.03
0.05
0.06
0.13
0.16
0.17
0.16
0.16
0.2
0.2
0.2
Dividend per Share
0.41
0.55
0.69
0.85
1.05
1.36
1.7
2.09
2.66
3.28
4.09
4.59
4.98
5.56
6.35
7.22
6.99
Book Value per Share
0.55
0.69
0.85
1.02
1.26
1.6
1.99
2.45
3.09
3.85
4.76
5.46
5.65
5.95
6.48
8.48
8.53
Tangible Book Value per Share
6,270
6,292
6,292
6,310
6,303
6,332
6,322
6,389
6,364
6,394
6,392
6,381
6,404
6,327
6,337
6,480
6,247
Basic Weighted Avg Shares
3,744
4,550
5,435
6,203
7,452
9,316
11,094
13,836
17,418
23,289
27,735
25,906
21,275
22,820
27,985
31,629
30,145
Sales/Revenue/Turnover
22.87
22.59
22.78
23.03
22.79
25.98
25.59
27.07
24.39
24.42
23.36
15.76
15.72
20.27
24.31
27.18
26.53
Operating Margin (%)
71
98
132
171
213
222
254
317
379
619
448
520
578
705
776
845
- -
Depreciation Expense
724
877
1,077
1,238
1,516
2,172
2,589
3,217
4,066
5,328
6,328
4,530
3,906
4,302
6,337
7,711
7,355
Net Income, GAAP
12.18
11.7
14.49
12.61
12.6
13.19
12.58
12.4
9.73
12.04
8.51
- -
3.86
8.34
11.61
11.38
13.05
Effective Tax Rate (%)
19.34
19.26
19.82
19.96
20.34
23.31
23.34
23.25
23.34
22.88
22.82
17.49
18.36
18.85
22.64
24.38
24.4
Profit Margin (%)
2,591
3,302
4,074
4,927
6,349
8,325
10,028
12,418
15,785
19,839
24,278
26,786
27,295
28,734
31,681
45,121
43,295
Working Capital
20
10
10
10
10
- -
- -
- -
- -
- -
- -
152
99
75
69
43
45
LT Debt
3,475
4,379
5,442
6,656
8,154
10,358
12,874
15,943
19,925
24,938
30,787
35,572
38,413
41,033
46,090
61,797
59,030
Total Equity
24.46
23.06
21.37
20.38
19.76
22.29
20.94
22.21
21.07
22.18
21.18
- -
8.51
10.46
13.69
13.96
13.51
Return on Invested Capital (%)
28.95
25.76
24.42
23.03
22.95
26.39
25.08
24.68
26.35
28
26.7
- -
12.54
12.44
16.52
17.47
17.87
Return on Capital (%)
31.87
29.07
27.61
25.46
25.21
28.47
26.74
26.67
26.85
28.13
26.85
16.34
12.77
12.83
16.8
17.72
18.16
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
41
46
46
LT Borrowings
- -
- -
- -
LT Finance Leases
69
63
45
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6,379
6,379
6,637
Market Capitalization
299,209
307,345
324,212

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
35,315
35,970
46,760
Cash, Cash Equivalents & STI
25,089
24,196
36,231
Accounts Receivable, Net
4,915
4,830
5,023
Inventories
2,417
2,401
2,581
Total Current Liabilities
3,634
3,363
3,465
Payables & Accruals
- -
- -
- -
ST Debt
41
46
46
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.85%
15.35%
34.08%
Free Cash Flow
-98.49%
-209.37%
51.71%
Net Income, GAAP
15.66%
7.39%
21.69%
Sales/Revenue/Turnover
14.09%
3.69%
13.02%
Total Cash Common Dividend
28%
5.23%
0.74%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,998
7,603
6,589
7,795
27,985
2025
7,206
8,556
8,441
- -
31,629
2026
8,141
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.21
- -
- -
- -
1
2025
0.3
- -
- -
- -
1.19
2026
0.34
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.2
2025
- -
- -
- -
- -
0.2
2026
- -
- -
- -
- -
- -
Similar Companies
Fangzhou Inc. (6086.HK)
Ono Pharmaceutical Co., Ltd. (4528.T)
Tdspharm (464280.KQ)
Tong Ren Tang Technologies Co. Ltd. (1666.HK)
Novartis AG (NVSEF)
Luye Pharma Group Ltd. (LYPHF)
Business
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SS; 1276.HK) develops, manufactures and markets innovative pharmaceuticals targeting oncology, metabolic and cardiovascular diseases, immunology and respiratory conditions, neuroscience, anesthesia, anti-infection and autoimmune disorders; its core products encompass new molecular entity drugs such as Apalutamide, Nab-paclitaxel (Hengli) and Otilimab, alongside surgical medicines, endocrine therapies, cardiovascular drugs, contrast agents, proteolysis-targeting chimeras (PROTACs), peptides, monoclonal antibodies, bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs) and radioligand therapies. Founded in 1970 and headquartered in Lianyungang, Jiangsu province, China, the company operates globally with R&D centers in China, the United States, Japan, Australia and Switzerland, subsidiaries in the US and Europe, and products available in over 40 countries including emerging markets; it maintains a pipeline of more than 100 innovative candidates across 400 clinical trials worldwide. In July 2025, Hengrui entered a landmark $500 million upfront collaboration with GSK to exclusively license HRS-9821 for chronic obstructive pulmonary disease and up to 11 additional preclinical candidates in respiratory, immunology, inflammation and oncology, with total potential value exceeding $12 billion; additional recent deals include a March 2025 agreement with Merck & Co. for oral lipoprotein(a) inhibitor HRS-5346 worth up to $1.97 billion and a May 2025 Hong Kong IPO raising $1.27 billion, alongside an exclusive license with Glenmark Pharmaceuticals for HER2 ADC Trastuzumab Rezetecan (SHR-A1811).